<DOC>
	<DOCNO>NCT00847795</DOCNO>
	<brief_summary>An exploratory Phase-II trial intradermal RN1001 ( Avotermin ) investigate scar prevention reduction acceleration healing . The trial additional objective evaluate several different scar assessment technique use future clinical trial prevention reduction scarring .</brief_summary>
	<brief_title>Efficacy Safety Intradermal RN1001 ( Avotermin ) Elderly Subjects .</brief_title>
	<detailed_description>Double blind , randomise , Placebo Standard Care control , single centre study . Each subject receive total 6 wound , two incision four punch biopsy . Each subject serf control , i.e . Arm 1 incisions/biopsies randomly receive one two treatment Arm 2 incisions/biopsies receive treatment Arm 1 reverse . The randomisation treatment allow control possible positional effect healing/scarring . Healed scar incisional wound excise Arm 1 Arm 2 6 month histological analysis .</detailed_description>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Clinically healthy , male female subject age 60 year . All female least 2 year post menopausal . Weight 50 150kg body mass index within permit range height use Quetelet 's indexweight ( kg ) /heightÂ² ( ) . The permitted index 15 35 kg/m2 . Subjects direct question physical examination history evidence hypertrophic keloid scar tattoos previous scar area biopsied . Subjects personal history bleed disorder . Subjects skin disorder chronic currently active investigator considers adversely affect heal acute wound involve area examine trial . Subjects clinically significant medical condition would impair wound heal include renal , hepatic , haematological , neurological immune disease . Subjects history clinically significant drug hypersensitivity lignocaine allergy surgical dressing use trial . Subjects clinically significant abnormality follow review pre trial laboratory data physical examination ( see ) . Subjects take , take , investigational drug , long term oral , topical inhale corticosteroid therapy , hormone replacement therapy ( HRT ) anticoagulant drug thirty day prior Day 0 . Subjects evidence drug abuse . Subjects know serum hepatitis carrier hepatitis B surface antigen hepatitis C antibody . Subjects previous vaccination Hepatitis B exclude per se . Subjects know serum hepatitis carrier hepatitis B core antibody show le 10 unit per litre AntiHBs . Subjects previously positive result test HIV antibody , admit belong highrisk group . In opinion investigator , subject likely complete trial ever reason .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>